# Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline

> **NCT02115256** · PHASE2,PHASE3 · TERMINATED · sponsor: **Yaakov Beilin** · enrollment: 6 (actual)

## Conditions studied

- External Cephalic Version

## Interventions

- **DRUG:** Intravenous Terbutaline
- **DRUG:** Intravenous Nitroglycerine

## Key facts

- **NCT ID:** NCT02115256
- **Lead sponsor:** Yaakov Beilin
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** difficult recruitment
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115256, "Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02115256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*